TrialCancer medicine2023

Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.

Matthew H Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.